NCT04552977 is a Phase 2 clinical trial of fluzoparil in Glioblastoma, sponsored by Shandong Cancer Hospital and Institute.

Who is sponsoring NCT04552977?

NCT04552977 is sponsored by Shandong Cancer Hospital and Institute.

What drugs are being tested in NCT04552977?

Interventions in NCT04552977: fluzoparil, temozolomide.

What condition does NCT04552977 study?

NCT04552977 studies Glioblastoma.

Is NCT04552977 still recruiting?

NCT04552977 is currently status unknown. Last updated 14 September 2020.

Last reviewed 2020-09-14 · How we verify

NCT04552977

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Status unknown Phase 2 Last updated 14 September 2020

What this trial tests

Phase 2 trial testing fluzoparil in Glioblastoma in 50 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 August 2021

1 August 2022

Quick facts

Lead sponsor	Shandong Cancer Hospital and Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 September 2020
Primary completion	1 August 2021
Estimated completion	1 August 2022

Drugs / interventions tested

fluzoparil — full drug profile →
temozolomide (temozolomide) — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Shandong Cancer Hospital and Institute

Who can join

Adults 18 to 70, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

6-months PFS rate in all participants by RECIST 1.1
Time frame: Up to approximately 24 months
6-months progression-free survival rate in all participants by RECIST 1.1

Sponsor's own description

This is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the efficacy and safety of fluzoparil combined with temozolomide in patients with recurrent glioblastoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.
Sim HW, Galanis E, Khasraw M. · · 2022 · cited 36× · PMID 35205750 · DOI 10.3390/cancers14041003
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, et al · · 2023 · cited 24× · PMID 36968138 · DOI 10.1158/2767-9764.crc-22-0436
Looking for the Holy Grail-Drug Candidates for Glioblastoma Multiforme Chemotherapy.
Pająk B. · · 2022 · cited 21× · PMID 35625738 · DOI 10.3390/biomedicines10051001
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.
Mekhaeil M, Dev KK, Conroy MJ. · · 2022 · cited 20× · PMID 35158955 · DOI 10.3390/cancers14030687
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.
Shen Y, Thng DKH, Wong ALA, Toh TB. · · 2024 · cited 12× · PMID 38615034 · DOI 10.1186/s40164-024-00512-8
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Gueble SE, Vasquez JC, Bindra RS. · · 2022 · cited 6× · PMID 36242713 · DOI 10.1007/s11864-022-01024-5

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Shandong Cancer Hospital and Institute trials

Trials by the same sponsor.

NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04552977 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
Last refreshed: 14 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04552977.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing